Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients
Journal of Atherosclerosis and Thrombosis · 01.07.2026 · 33 (7) · 979-991
DOI: 10.5551/jat.66069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Atherosclerosis and Thrombosis, erschienen am 01.07.2026. Verfasst von Kazuma Oyama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Atherosclerosis, Cardiovascular Diseases. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
AIMS: Lowering low-density lipoprotein cholesterol (LDL-C) is essential for reducing the risk of atherosclerotic cardiovascular disease (ASCVD). This study assessed the clinical efficacy of evolocumab, a human monoclonal antibody targeting PCSK9, in Japanese patients using data from the PROFICIO program. METHODS: Data were pooled from Japanese participants enrolled in five clinical trials: YUKAWA-1, YUKAWA-2, OSLER-1, OSLER-2, and FOURIER. The primary endpoint was percent change in LDL-C from baseline to Week 12. Secondary endpoints included changes in other lipid parameters, achievement of LDL-C targets, incidence of major adverse cardiovascular events (MACE), and subgroup analyses. RESULTS: A total of 1,040 patients with high cardiovascular risk or established ASCVD were included. At Week 12, the mean percent reduction in LDL-C was 75.7% with evolocumab compared with 1.3% with placebo (least-square mean treatment difference: ‑75.0%; 95% confidence interval [CI]: -76.7 to -73.4; p<0.001), which was consistent across subgroups. Other lipid parameters showed directionally consistent percent changes, with variable magnitudes across markers. Overall, 92.9% of patients treated with evolocumab achieved an LDL-C <55 mg/dL at Week 12 compared with 0.8% of patients in the placebo group. In FOURIER, over a median follow-up of 2.1 years, incidence of MACE was lower with evolocumab than placebo (5.9% vs. 12.4%; hazard ratio: 0.47; 95% CI: 0.24-0.92). Treatment effects on MACE were consistent in both primary and secondary prevention groups (pooled odds ratio: 0.42; 95% CI: 0.23-0.79). CONCLUSION: Evolocumab significantly and consistently lowered LDL-C and reduced the risk of MACE in Japanese patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.
- Life Science and Bioethics Center, Institute of Tokyo Science.
- Department of Cardiology, Moriyama Memorial Hospital.
- Medical Affairs, Amgen K.K.
- Biostatistics, Amgen K.K.
- Real World Evidence, Syneos Health.
Zitieren
APA
Oyama, K., Yoshida, M., Kiyosue, A., Osada, N., Sheng, F., Harada, N., Miyawaki, K., Shimauchi, J., Fu, Y., & Yamashita, S. (2026). Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients. Journal of Atherosclerosis and Thrombosis, 33(7), 979-991. https://doi.org/10.5551/jat.66069
Vancouver
Oyama K, Yoshida M, Kiyosue A, Osada N, Sheng F, Harada N, et al. Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients. Journal of Atherosclerosis and Thrombosis. 2026;33(7):979-991. doi:10.5551/jat.66069
BibTeX
@article{Oyama2026,
author = {Oyama, Kazuma and Yoshida, Masayuki and Kiyosue, Arihiro and Osada, Nobuhiro and Sheng, Feng and Harada, Naozumi and Miyawaki, Kazumasa and Shimauchi, Junichiro and Fu, Yang and Yamashita, Shizuya},
title = {Clinical Efficacy with Evolocumab among Japanese Patients in PROFICIO: A Pooled Analysis of 1,040 Patients},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2026},
volume = {33},
number = {7},
pages = {979--991},
doi = {10.5551/jat.66069}
}
EUVIMED